Previous Close | 1.5000 |
Open | 1.5500 |
Bid | 1.4200 x 1000 |
Ask | 1.7000 x 900 |
Day's Range | 1.5500 - 1.6000 |
52 Week Range | 0.7500 - 1.8800 |
Volume | |
Avg. Volume | 77,691 |
Market Cap | 94.365M |
Beta (5Y Monthly) | 1.29 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.4060 |
Earnings Date | Sep 20, 2022 - Sep 26, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for AKTX
NEW YORK and LONDON, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that it is prioritizing two pipeline programs. Cash and resources will be reallocated to the Phase 3 clinical trial of nomacopan in severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), with Part A data expected in the first half of 2023
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Positive results from recent pre-clinical studies support the potential of long-acting PASylated nomacopan to advance toward IND/IMPD for clinical trials in geographic atrophy (GA) in dry age-related macular degeneration (dAMD), a disease with no approved treatmentsNew PK measurements indicate the half-life within the eye of intravitreally injected early generation PAS-nomacopan (also referred to as PAS600 nomacopan) in a standard ophthalmic pre-clinical model can be accurately predicted; result